JP2018516279A - 経口投与用のセレコキシブの液状配合物 - Google Patents

経口投与用のセレコキシブの液状配合物 Download PDF

Info

Publication number
JP2018516279A
JP2018516279A JP2018513730A JP2018513730A JP2018516279A JP 2018516279 A JP2018516279 A JP 2018516279A JP 2018513730 A JP2018513730 A JP 2018513730A JP 2018513730 A JP2018513730 A JP 2018513730A JP 2018516279 A JP2018516279 A JP 2018516279A
Authority
JP
Japan
Prior art keywords
celecoxib
pharmaceutical formulation
liquid pharmaceutical
amount
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018513730A
Other languages
English (en)
Japanese (ja)
Inventor
キール，ジェフリー・スコット
ブライアント，トーマス・ジェフリー
ルバスール，リチャード・ゲラルド
トーマス，ヒュー・グレッグ
Original Assignee
コーダドース・インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コーダドース・インコーポレーテッド filed Critical コーダドース・インコーポレーテッド
Publication of JP2018516279A publication Critical patent/JP2018516279A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
JP2018513730A 2015-05-29 2016-05-24 経口投与用のセレコキシブの液状配合物 Pending JP2018516279A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562168012P 2015-05-29 2015-05-29
US62/168,012 2015-05-29
US15/163,258 US20160346300A1 (en) 2015-05-29 2016-05-24 Liquid formulations of celecoxib for oral administration
PCT/US2016/033937 WO2016196085A1 (en) 2015-05-29 2016-05-24 Liquid formulations of celecoxib for oral administration
US15/163,258 2016-05-24

Publications (1)

Publication Number Publication Date
JP2018516279A true JP2018516279A (ja) 2018-06-21

Family

ID=57396976

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018513730A Pending JP2018516279A (ja) 2015-05-29 2016-05-24 経口投与用のセレコキシブの液状配合物

Country Status (9)

Country Link
US (1) US20160346300A1 (enExample)
EP (1) EP3302430A4 (enExample)
JP (1) JP2018516279A (enExample)
AU (1) AU2016270504A1 (enExample)
BR (1) BR112017025527A2 (enExample)
CA (1) CA2987388A1 (enExample)
MX (1) MX2017015202A (enExample)
RU (1) RU2017145602A (enExample)
WO (1) WO2016196085A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016191744A1 (en) * 2015-05-28 2016-12-01 Dr. Reddy's Laboratories Ltd. Oral composition of celecoxib for treatment of pain
WO2022185338A1 (en) * 2021-03-05 2022-09-09 Alkem Laboratories Limited Stable oral suspension of celecoxib and method of preparation thereof
CN115737554B (zh) * 2022-11-28 2024-07-09 宜昌人福药业有限责任公司 一种氯巴占口服混悬剂的制备方法
WO2024142089A1 (en) * 2022-12-27 2024-07-04 Cipla Limited Injectable compositions of celecoxib

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001052897A2 (en) * 2000-01-21 2001-07-26 Panacea Biotec Limited Therapeutic anti-inflammatory and analgesic composition containing selective cox-2 inhibitors
JP2004500427A (ja) * 2000-04-18 2004-01-08 ファルマシア・コーポレーション 選択的シクロオキシゲナーゼ−２阻害薬の即効性製剤
JP2005500363A (ja) * 2001-08-06 2005-01-06 ファルマシア・コーポレーション 安定化経口懸濁液製剤

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4145440A (en) * 1977-08-18 1979-03-20 The Upjohn Company Liquid suspension of an aluminum salt of ibuprofen
AR035642A1 (es) * 2000-05-26 2004-06-23 Pharmacia Corp Uso de una composicion de celecoxib para el alivio rapido del dolor
US6656505B2 (en) * 2000-07-21 2003-12-02 Alpharma Uspd Inc. Method for forming an aqueous flocculated suspension
US20030105144A1 (en) * 2001-04-17 2003-06-05 Ping Gao Stabilized oral pharmaceutical composition
US7101572B2 (en) * 2001-12-07 2006-09-05 Unilab Pharmatech, Ltd. Taste masked aqueous liquid pharmaceutical composition
PL371133A1 (en) * 2001-12-20 2005-06-13 Pharmacia Corporation Pharmaceutical suspension for oral administration
AU2003238221A1 (en) * 2002-06-17 2003-12-31 Taro Pharmaceuticals U.S.A, Inc. Ibuprofen suspension
US20060148877A1 (en) * 2002-11-26 2006-07-06 Transform Pharmaceuticals, Inc. Pharmaceutical formulations of celcoxib
US20050014729A1 (en) * 2003-07-16 2005-01-20 Pharmacia Corporation Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
US20050266031A1 (en) * 2004-05-25 2005-12-01 Jay Dickerson Pharmaceutical suspension composition
US20080014274A1 (en) * 2006-07-14 2008-01-17 Wyeth Enhanced stability phenylephrine liquid compositions
US20110183944A1 (en) * 2010-01-28 2011-07-28 Paul Ashton SUSTAINED-RELEASE NSAID/HMG CoA REDUCTASE INHIBITOR COMPOSITIONS
EP3530268B1 (en) * 2012-10-09 2021-12-15 Attentive Therapeutics, Inc. Therapeutic treatment
CN103932977A (zh) * 2014-04-15 2014-07-23 江苏正大清江制药有限公司 一种塞来昔布制剂的制备方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001052897A2 (en) * 2000-01-21 2001-07-26 Panacea Biotec Limited Therapeutic anti-inflammatory and analgesic composition containing selective cox-2 inhibitors
JP2004500427A (ja) * 2000-04-18 2004-01-08 ファルマシア・コーポレーション 選択的シクロオキシゲナーゼ−２阻害薬の即効性製剤
JP2005500363A (ja) * 2001-08-06 2005-01-06 ファルマシア・コーポレーション 安定化経口懸濁液製剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
INT J PHARM COMPD, vol. 14, no. 3, JPN6020012780, 2010, pages 242, ISSN: 0004371314 *

Also Published As

Publication number Publication date
MX2017015202A (es) 2018-07-06
RU2017145602A3 (enExample) 2019-11-25
AU2016270504A1 (en) 2017-12-14
CA2987388A1 (en) 2016-12-08
US20160346300A1 (en) 2016-12-01
WO2016196085A1 (en) 2016-12-08
RU2017145602A (ru) 2019-07-02
EP3302430A4 (en) 2019-05-29
EP3302430A1 (en) 2018-04-11
BR112017025527A2 (pt) 2018-08-07

Similar Documents

Publication Publication Date Title
JP7489965B2 (ja) マルチキナーゼ阻害剤のエマルジョン製剤
KR101053780B1 (ko) 도세탁셀을 함유하는 단일액상의 안정한 약제학적 조성물
FI95773C (fi) Menetelmä vesipitoisen, N-(3,4-dimetoksikinnamoyyli)antraniilihappoa sisältävän farmaseuttisen koostumuksen valmistamiseksi
US8765150B2 (en) Riluzole aqueous suspensions
MXPA06013481A (es) Composicion de suspension farmaceutica.
WO2012005973A1 (en) Posaconazole intravenous solution formulations stabilized by substituted beta-cyclodextrin
JP2018516279A (ja) 経口投与用のセレコキシブの液状配合物
WO2011047637A1 (zh) 一种含有pH值调节剂的紫杉烷类药物溶液及其制备方法
WO2023222660A1 (en) Aqueous ticagrelor solutions, method of manufacturing and uses
WO2023222184A1 (en) Aqueous ticagrelor solution, method of manufacturing and uses
JPWO2018043613A1 (ja) 水性懸濁型製剤
JPH0536412B2 (enExample)
US20070244085A1 (en) Injectable or orally deliverable formulations of azetidine derivatives
JP4475405B2 (ja) 医薬組成物
EP3644968B1 (en) Levocloperastine fendizoate suspension having enhanced dissolution and resuspendability
US11517522B2 (en) Aprepitant ready-to-use injection emulsion compositions
WO2021033145A1 (en) Novel injectable formulations of artesunate
WO2023148763A1 (en) Injectable pharmaceutical compositions of azole antifungal agents
US20240415778A1 (en) Oral preparation containing progestogen, and preparation method and use
JP2006160696A (ja) 難水溶性薬剤用可溶化剤組成物
KR100299942B1 (ko) 비페닐디메칠디카르복실레이트의액제
KR20250067929A (ko) 벨루모수딜의 액체 제형
WO2025104277A1 (en) Ticagrelor iv for use in the treatment, reduction or prevention of an ischemic event in a patient undergoing a percutaneous coronary intervention (pci)
WO2021199076A1 (en) Injectable aripiprazole formulation

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20180412

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180412

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190424

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200401

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200701

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20201022